Introduction
Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor in children. Found in diverse anatomic sites, diagnosis of RMS is based on detection of signs of skeletal muscle dierentiation. This can include evidence at the light microscopic level, i.e. cross-striations, or immunohistochemical detection of structural proteins such as a-actin, desmin, and regulatory proteins such as myogenin and MyoD1. Other than this apparent common myogenic lineage, RMS is a heterogeneous tumor with varying histological and clinical presentations. Two major histological subtypes are de®ned, namely embryonal (RMS-E) and alveolar (RMS-A) with RMS-A being clinically more aggressive. RMS with mixed embryonal and alveolar histology occasionally occurs and behaves more like RMS-A. Despite great improvement over past decades with multi-modal therapy, the 5-year survival rate of RMS remains at about 65 ± 70% with most metastatic cases still fatal. Conventional therapeutic modalities maybe approaching their limit in bringing about further improvements in RMS outcome. However oncogenomic methodologies now oer opportunities for identifying new classes of tumor-speci®c genes that may lead to more targeted therapeutic approaches (reviewed in Merlino and Helman (1999) ; Dagher and Helman (1999) and Anderson et al. (1999b) ).
RMS heterogeneity is also re¯ected on the molecular level. RMS-E is commonly associated with a loss of heterozygosity (LOH) on chromosomal region 11p15.5 suggesting that one or more tumor suppressor genes may map to this region. Putative candidate tumor suppressor gene(s) in this region include H19, p57KIP2, KVLQT1, GOK, TSSC1, BWR1A and BWR1C (reviewed in Anderson et al. (1999b) ). Comparative genomic hybridization (CGH) and spectral karyotyping (SKY) analysis of RMS genome showed that numeric changes were more common in RMS-E, while structural changes were more prominent in RMS-A (Pandita et al., 1999) . In RMS-A, the most obvious structural changes are the t(2;13) and t(1;13) translocations. The majority of RMS-A possess one of these translocations which involve the in-frame fusion of PAX3 or PAX7 gene to the FKHR transcriptional activator. Resultant chimeric proteins were found to be more potent transcriptional regulators. The potential gain-of-function was thought to contribute to the more aggressive behavior of RMS-A (reviewed in Barr (1997) ).
Recent data are beginning to suggest that LOH at 11p15.5 is not exclusive to RMS-E (Anderson et al., 1999a; Visser et al., 1997) , and that molecular changes in RMS between, as well as within, subtypes are more complex and heterogeneous than previously believed. The use of genomic screening technologies is increasingly proving to generate new candidate markers suited for diagnostic and prognostic purposes. In this study, we have used Representational Dierence Analysis (RDA) to compare gene expression between RMS-E and RMS-A. RDA allows the isolation of novel genes at a manageable scale and oers greater sensitivity than the traditional subtractive hybridization. It is a PCR-based subtractive hybridization technique that had been employed successfully in identifying dierences between two very similar DNA or cDNA populations (Hubank and Schatz, 1994; Lisitsyn et al., 1993) . Its application in cancer research includes the identi®cation of the tumor suppressor gene PTEN (Li et al., 1997) , the family of tumor speci®c genes MAGE (Lucas et al., 1998) , as well as the isolation of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma (Chang et al., 1994) . As RDA requires only minute amount of starting RNA, it is ideal for screening a rare tumor such as RMS in which tumor tissue is often limited.
Results

Difference products isolated by RDA
To compare gene expression by RDA, RMS-A and RMS-E cDNA was used as tester in the forward and reverse subtraction, respectively. After three rounds of RDA subtraction and ampli®cation, 44 clones were selected for initial dot-blot screening. Of these, 13 clones showed dierential signal intensity (Figure 1) . Sequencing of these 13 clones revealed ®ve unique sequences, designated C1 to C5. C1 was obtained from the forward subtraction suggesting higher expression in RMS-E. C2 to C5 were products of the reverse subtraction and thus were likely to have higher expression in RMS-A. Sequence identities of C1 to C5 were shown in Table 1 . Semi-quantitative analysis was performed to con®rm dierential expression in the four samples originally used in RDA (Figure 2 ). Follow-up analysis was focused on C2 and C3 which showed the greatest dierence in signal strength between RMS-A and RMS-E. As indicated in Table  1 , C2 and C3 showed no nucleotide sequence homology to any known gene in GenBank. However, matches to human ESTs and high throughput genomic sequences (HTGS) were found. Homologies to mouse and rat ESTs were also present.
Confirmation of differential expression of selected RDA products by semi-quantitative RT ± PCR To assess relative expression level of C2 and C3 in RMS tumors, a series of 53 RMS tumors were screened with semi-quantitative RT ± PCR with sequence speci®c Figure 1 Reversed dot-blot array screening of RDA products. After the cloning of RDA products, 44 clones were individually dot-blotted onto duplicate membranes. 32 P-labeled RDA 3rd dierence products were used as complex probes on each membrane. Membrane on left was probed with cDNA enriched with RMS-A sequences, while the one on right was probed with cDNA enriched with RMS-E sequences. Thirteen clones (underlined) with dierential signal intensity were detected, of which 12 gave stronger signals with RMS-A probe (Table 2) . Dierences in expression level of both C2 and C3 between RMS-A group and RMS-E group of tumors were found to be statistically signi®cant (P50.02, Mann-Whitney Rank Sum statistics).
Isolation of full-length cDNA with various splice forms
To determine transcript size, Northern blot was performed with one RMS-A and one RMS-E total RNA. Probing with C3 gave rise to a strong signal of 1.25 kb in RMS-A ( Figure 4) . Very weak signals of 1.8 ± 2.0 kb were detected in normal brain, testis and liver using C2 as probe with a commercially available poly(A) + mRNA multiple tissue Northern blot (not shown).
To isolate the full-length cDNA, C2 and C3 were used as template in RACE reactions. Only the 3' reaction of C3 yielded a clean band, termed C3-3G. This sequence is of 775 bp, contains a poly(A) tract but no polyadenylation signal. C3-3G showed sequence identity with human ESTs as well as HTGs. There was no match to known gene but homologies to mouse and rat ESTs were present. Comparison to HTGS showed that C3-3G contained 2 exons ( Figure 5 ).
Since similar expression patterns were noted for C2 and C3 (Figure 3 ), it was suspected that they could possibly be dierent segments of the same gene. As RACE was unable to isolate the full-length sequence, PCR was performed using one primer from each Figure 2 Expression screening of C1 to C5 by RT ± PCR. Relative expression levels of C1 to C5 were assessed by RT ± PCR in the four RMS tumor samples used in RDA. Lanes 1 and 2 are the RMS-A samples and lanes 3 and 4 are RMS-E samples. Expression of the housekeeping gene PBGD was also determined for comparison. De®nite dierential expressions between RMS-A and RMS-E were noted for C2, C3 and C4 Figure 3 Expression screening of C2 and C3 by semi-quantitative RT ± PCR. A series of RMS-E and RMS-A were screened for C2 and C3 expression by semi-quantitative RT ± PCR. C2 and C3 overall expression were higher in RMS-A (lanes 40 ± 52) and in RMS with mixed alveolar-embryonal histology group (lanes 33 ± 38) than in RMS-E (lanes 1 ± 32), though variability between individual cases existed. Level of C2 and C3 were expressed as ratios to the housekeeping gene PBGD for statistical analysis (Table 2) . Signi®cant dierences were found between RMS-A and RMS-E tumors for both C2 and C3 expression (Mann-Whitney Rank Sum statistic, P50.02). *This case was re-classi®ed as the solid variant of RMS-A after pathology review. Lane L denoted DNA size ladder, lanes 54 and 55 were RMS with no subtype information, lane 57 was a sample of normal muscle and lane 58 was the negative water control sequence. A larger product, named C23up (GenBank Accession #AF429305), was ampli®ed, puri®ed and sequenced. C23up is 1103 bps long and contains C2 and C3 sequences at both ends with additional intervening sequence ( Figure 5 ). Like the original C2 and C3 sequences, C23up showed sequence identity to human ESTs and HTGS. There was no homology to any known gene in GenBank but homologies to mouse and rat ESTs were again noted. The whole sequence matches to two BAC clones on chromosome band 12q21 with over 99% homology. Alignment of C23up with genomic sequences revealed at least seven exons with conserved splice sites ( Figure 5 ). Multiple stop codons were noted in all six frames and the longest possible open reading frame (ORF) was less than 300 bps. However, none of the ORF fell within a strong, favorable context (Kozak, 1996) .
Using C23up as a probe, a fetal brain phage library was screened yielding three positive clones with a consensus sequence designated as C-con (GenBank Accession #429306). C-con is 1375 bps in length and again showed no homology to known gene in GenBank. Human, mouse, rat, pig and cow ESTs matched dierent segments along the whole sequence. Complete C-con sequence revealed 100% identity to chromosome 12 HTGS. These HTGS were from the same two BAC clones that matched to C23up, with transcript alignment variation that was suggestive of alternative splicing. Like C23up, C-con also contained seven exons with four exons the same as those in C23up. The alignments of C23up and C-con in relation to each other and to the genomic sequence are shown in Figure 5 . In comparison to C23up, C-con has one less exon (exon 6) of 127 bps. Primers¯anking exon 6 were used in PCR and products with (C23up) or without (C-con) this exon were found in RMS-A, RMS-E, as well as normal muscle. Expression was strongest in RMS-A with the product representing C23up more prominent (Figure 6 ). With C23up and Ccon representing alternatively splice forms, we named this gene NCRMS.
The longest possible ORF in any of the six reading frames for C-con was less than 300 bps and none was with a favorable context which appeared the same as that of C23up. This suggested that NCRMS was unlikely to encode a protein product. One end of the C-con sequence matched to multiple human ESTs that belong to the same UniGene cluster. Based on the poly-A tract location of these ESTs, this end of C-con is likely the 3' end of the gene. A closer look at the alignment between these ESTs to C-con revealed that the alignment ceased 6 bps before the end of C-con, at which the polyadenylation signal AATAAA began in these ESTs. The poly-A tracts in these ESTs were found 14 bp downstream. C-con did not have the polyadenylation signal and no poly-A tract was found. Comparison of the EST consensus sequence to HTGS showed that, unlike C-con, these ESTs were not spliced ( Figure 5 ). Assembling a consensus sequence with C2, C3, C23up and C-con resulted in a sequence of about 1.8 ± 1.9 kb which was the size re¯ected from the multiple tissue Northern blot. However, no signi®cant ORF characteristic of a typical gene was identi®ed.
Chromosomal location of NCRMS
The two BAC clones containing the HTGS that match to NCRMS sequence lie side by side on chromosome 12q21 between markers D12S1657 and D12S1279 (197 kbs apart) near stSG58190. This location was con®rmed in parallel by radiation hybrid mapping of the C3 sequence. Approximately 16 Mb away towards the centromeric end lie the Myf5, Myf6 and ATP2B1 (C1) genes, and about 6 Mb towards the telomeric end lies the Igf1 gene (Figure 7 ). Figure 5 Gene structure of NCRMS. Alignments and relationships of various sequences, C2, C3, C23up, C-con, 3' RACE fragment (C3 ± 3G), ESTs consensus and HTGS sequences, revealed the gene structure of NCRMS. Numbers in boxes are exon numbers Figure 6 RT ± PCR with primers¯anking exon 6. The presence of both alternatively spliced transcripts, C23up (with exon 6) and C-con (without exon 6), was demonstrated by RT ± PCR with primers¯anking exon 6. Products of expected sizes, 373 bps with exon 6 and 247 bps without, were resulted
Differential expression of NCRMS in various tumors
Expression of NCRMS was further assessed in various tumor types using the primers¯anking exon 6. Both splice forms, C23up and C-con showed dierential expression between tumor types (Figure 8 ). Most tumor types showed weaker expression level than RMS except synovial sarcoma and neuroblastoma that showed comparable expression level of NCRMS as RMS.
Discussion
To broaden our knowledge in the tumorigenetic pathways of RMS, we began our study in comparing gene expression between the two major subtypes in RMS. By RDA, we isolated two sequences, C2 and C3, both with higher expression in most RMS-A when compared to RMS-E. Based on these two sequences, other related sequences were isolated by RACE (C3-3G), PCR (C23up) and cDNA library screening (Ccon) which all indicated alternative splicing of a single gene we termed NCRMS. Sequence analysis of NCRMS indicated that all these sequences had no homology to any known gene deposited in GenBank as of June 11, 2001 . However, they all showed 99+ per cent identity to human genomic sequences. Introns and exons were identi®ed in these sequences with conserved splice sites. Alternative splicing of NCRMS was especially evident between C23up and C-con. With clear intron and exon structure, it is unlikely that these are pseudogenes.
Though multiple stop codons were present and thus no signi®cant ORF was found in all frames, functions of these sequences were implicated through their signi®cant homologies to various ESTs within and across species. As no typical ORF was found, it would be dicult to de®ne the full-length transcript. However, based on comparison with transcript size determined by Northern Blot, it is likely that the fulllength sequence has been obtained. The limited potential available for protein coding suggests that NCRMS is an example of non-coding RNA (ncRNA) (Erdmann et al., 2001) .
Non-coding RNA are mRNA transcripts that function merely as RNA and are not thought to encode a protein product. These RNA species do not conform to the well-accepted genetic paradigm of function after translation', and it is probable that many ncRNA went unrecognized for many years so there is not an extensive literature on these intriguing molecules. In addition, most gene annotating softwares are designed to examine ORFs, the protein coding region, when de®ning a gene so that awareness of this class of RNA is limited. More data is available from two relatively well-studied ncRNA, XIST and H19.
XIST was expressed exclusively from the inactivated X chromosome in human and is known to directly participate in the dosage-compensation process between male and female. XIST transcripts were found to physically coat the X chromosome to prevent expression of target genes. Its function is also in cooperation with tsix which is an anti-sense transcript of XIST (Brown et al., 1992) . H19 is a developmentally regulated gene that maps to the imprinted chromosomal region 11p15.5 with Igf2. It was found to regulate Igf2 expression in a complex manner involving an imprinting mechanism and dierential allelic methylation (Srivastava et al., 2000; Thorvaldsen et al., 1998) . Since these ncRNA are involved in regulating the expression of nearby genes, they are also referred as riboregulators (Erdmann et al., 2001) . This group of RNA may contain poly-A tract or repeats, involve alternative splicing, and they can be associated with disease or imprinting. Since there is currently no common characteristic to ncRNA, it is dicult to postulate a precise function to the NCRMS transcript.
The chromosomal location of NCRMS at 12q21 may be important in the etiology of this muscle tumor. Two myogenic genes, Myf5 and Myf6 are located on chromosome 12q21, about 16 Mb centromeric from NCRMS. In addition, the human plasma membrane Ca(2+)-ATPase gene (ATP2B1) (RDA clone C1) maps adjacent to Myf5. 6 Mb telomeric from NCRMS is the insulin-linked growth factor 1 gene (Igf1). IGF1 protein, a structural homolog of IGF2, was shown to stimulate skeletal muscle hypertrophy (Musaro et al., 1999) . Since gene expression dysregulation is suggested in this chromosomal region associated with myogenesis, a complex mechanism in gene regulations is likely involved.
In summary, our data suggest that the chromosomal region 12q21 may be important in myogenesis and the development of RMS. We have identi®ed a novel gene NCRMS in this region which could act as a ncRNA. A possible alternative pathway in RMS tumorigenesis may involve gene regulation by NCRMS. Comparable expression level of NCRMS in synovial sarcoma and neuroblastoma may suggest a common pathway utilized by these tumors. Further investigations are needed to con®rm this hypothesis and to study the complex interaction of genes that are involved in RMS tumorigenesis.
Materials and methods
Tumor samples
RMS patient tumor tissues were obtained from the frozen tumor bank in the department of Paediatric Laboratory Medicine (Division of Pathology) in the Hospital for Sick Children. Specimens were obtained after informed consent was received from all parents/guardians of children at diagnosis. A total of 32 RMS-E, 13 RMS-A, six RMS with mixed alveolar and embryonal histology, two histologically unclassi®ed RMS, and one normal muscle sample were included. Cryosections of selected samples were reviewed and those with at least 90% tumor without extensive necrosis were selected. Total RNA was extracted with TRIzol Reagent (GIBCO BRL 15596). Only good quality RNA showing strong and discrete bands of the 18S and 28S ribosomal RNA upon gel electrophoresis was used. Four RMS samples, two RMS-E and two RMS-A, one with t(1;13) and the other with t(2;13) translocation, were selected for subtractions in RDA. RDA was carried out as previously described (Lisitsyn et al., 1993) with slight modi®cations as outlined below. Unless otherwise stated, manufacturers' protocols were followed closely.
Additional frozen tissues or RNA of various tumor types were obtained from dierent research laboratories in Toronto for subsequent dierential screening and that included four cases of breast cancer; three cases each of synovial sarcoma, leiomyosarcoma, ®brosarcoma, neuroblastoma, Ewings sarcoma, osteosarcoma, colon cancer; two cases of Wilm's tumor and a case of lymphoma.
Unless otherwise stated, manufacturers' protocols were followed closely.
Synthesis of first and second strand cDNA cDNA was synthesized from each tumor RNA individually. Five mg of RNA was ®rst treated with DNaseI (GIBCO ± BRL 18068-015), then reverse transcribed with Superscripts II (GIBCO ± BRL 18064-014). cDNA-RNA hybrid was puri®ed with QIAquick PCR-puri®cation column (QIAGEN 28104). Second strand cDNA was synthesized by incubating overnight the above cDNA ± RNA hybrid in RNase H (4 U), E. coli DNA Ligase (20 U), E. coli T4 DNA Polymerase (8 U), and dNTPs (160 mM) in a total volume of 150 ml. Resultant double-stranded cDNA was gel puri®ed with QIAEX II (QIAGEN 20021) . cDNA of the same RMS subtype were pooled after completing the 2nd strand synthesis.
Representational difference analysis
RDA was carried out as previously described using SAU 3A I (NEB 169CL) and the set of Bam oligo adaptors with three rounds of hybridizations and PCR ampli®cations (Lisitsyn and Wigler, 1995) . In the forward subtraction, RMS-E cDNA was used as tester for the identi®cation of genes with higher expression in RMS-E; while in the reverse subtraction, RMS-A cDNA was used as tester to identify genes with higher expression in RMS-A.
Analysis of RDA products
RDA third dierence products from both subtractions were resolved on agarose gel. Selected bands or smears, when bands were too close to be separated, were gel puri®ed and cloned with pUC19 plasmid (GIBCO ± BRL 15364-011) and DH-5a competent cells (GIBCO ± BRL 18265-017). For initial screening, PCR products of inserts from 44 selected clones were dot-blotted on duplicated nylon membranes. Membranes were then probed with 32 P-labeled RDA 3rd dierence products, one from each direction of subtraction. Clones that showed dierential signal intensity were sequenced for semi-quantitative PCR analysis.
Semi-quantitative PCR analysis
First strand cDNA was generated from total RNA as described above. Using 1/10 of reversed transcription product as template, PCR were performed for each sample with gene speci®c primers for C2 and C3, as well as primers for the housekeeping gene Porphobilinogen Deaminase (PBGD). Primers used are as follows: PBGD 5'-CAT GTC TGG TAA CGG CAA TGC GGC TGC-3' and 5'-GAA CTC CAG ATG CGG GAA CTT TC-3' with product size of 490 bps; C2 5'-CAC GGA GTC AAC AGA AAA-3' and 5'-TGT GCT GAG TGG AGT AAC-3' with product size 155 bps; C3 5'-GCA CCT TGG AAA GAA TAG-3' and 5'-CCA GGG TTA TCT CAC AAC-3' with product size 126 bps. 50 ml reactions were set up containing a ®nal 1 mM of each primer, 200 mM dNTPs, 2.5 mM MgCl 2 , 1X Perkin Elmer PCR buer II, and 2.5 U of Taq Polymerase Gold (Perkin Elmer). PCR was performed with initial denaturization and activation at 958C for 10 min, followed by 35 cycles of 958C for 30 s, 528C for 45 s, and 728C for 45 s. A ®nal extension was done for 10 min at 728C. PCR products were visualized by gel electrophoresis with ethidium bromide. Gel images were digitally captured over UV. Intensities of all bands were measured by software NIH Image 1.60. Relative expression level of C2 and C3 in each sample was calculated as ratios of C2/PBGD and C3/PBGD. Dierences in C2 and C3 expression between RMS-A and RMS-E groups of tumors were assessed with Mann ± Whitney Rank Sum statistic.
Northern blot analysis
Ten mg of total RNA from one RMS-A and one RMS-E tumor were resolved on formaldehyde agarose gel and alkaline transferred to a positively charged nylon membrane. C3 PCR product was gel-puri®ed and labeled with 32 P by random priming (Boehringer Mannheim 1004 760). Probing was done at a speci®c activity of 1.56610 6 c.p.m. in 10 ml of Hybrisol (Oncor S4040) in hybridization oven overnight at 428C. After hybridization, membrane was washed four times: once in 26SSC+1% SDS, once in 0.26SSC+0.1% SDS, and twice in 0.16SSC+0.1% SDS at 688C. The membrane was then allowed to expose overnight at 7808C to autorad ®lm.
Multiple tissues Northern blot was obtained from OriGene (HB-2010) with 12 dierent normal human Poly(A) + mRNA. Two dierent ways of probe-labeling were done. Strippable probes were PCR generated and labeled with 32 P by Strip-EZ PCR (Ambion 1475). Regular probe was labeled by random priming as above with 32 P. Overnight hybridization was carried out as described above but in UltraHyb (Ambion 8670). Probing and washing procedures were also the same as above. Signals were detected with phosphor screen.
Rapid amplification of cDNA ends (RACE)
SMART RACE cDNA ampli®cation kit (Clontech K1811-1) was used to amplify both the 5' and 3' ends of target sequences. Sequence-speci®c primers were designed to match with the special end primers provided with the kit for use in PCR ampli®cation. The sample used in RACE was a case of RMS-A that showed strong expression of target sequences. PCR reactions were optimized to amplify a single product. Nested PCR was performed when primary PCR failed to result in a single product. PCR products were resolved in agarose gel and puri®ed with QIAEX II (QIAGEN 20021), T-tailed cloned into pUC19 plasmid and transformed into DH5a competent cells. Positive clones were sequenced and analysed.
Phage library screening
A commercially available fetal brain phage library (Stratagene 936206) was screened with 32 P-labeled C23up PCR product according to standard protocol (Sambrook et al., 1989) . A total of three rounds of screening were performed. Individual positive phage clones were converted back to plasmid, cloned according to ZAP-cDNA synthesis kit (Stratagene 200403) and sequenced for further analysis.
NCRMS expression screening
For PCR¯anking exon 6, 20 ml reactions were set up containing a ®nal 1 mM of each primers, 200 mM dNTPs, 2.5 mM MgCl 2 , 1X Perkin Elmer PCR buer II, and 1 U of Taq Polymerase Gold. PCR templates were 1 ml of RT product (1st strand cDNA). Primers¯anking exon 6 are: 5'-CCG ATT ATT ACC AAA GAC AAT G-3' and 5'-TCC GTG TCC CTT GTG ATC TCT G-3'. PCR product size is 373 bps with exon 6 (C23up) and 247 bps without exon 6 (Ccon). PCR condition used were as follows: Initial denaturization at 958C for 10 min; 40 step cycles of 958C for 35 s, 558C for 40 s, 728C for 1 min; ®nal extension 728C for 10 min. PCR products were visualized by gel electrophoresis in 1% agarose gel containing ethidium bromide.
